DPHARMA DUOPHARMA BIOTECH BERHAD
DPHARMA scores 85/100 on fundamentals: in the top 3% of 1120 scored Bursa Malaysia stocks. Its strongest area is Risk (100/100); its weakest is Cash & Dividends (75/100). It carries 1 warning flag: Low-Price Yield.
- Carries a Low-Price Yield flag
Nearby peers
Ranks #1 of 30 in Health Care by score
One-Minute Summary
Why DPHARMA scores 85
A financially strong, inexpensively priced stock with healthy growth, but cash & dividends needs attention.
After Jun '26 results: 76 → 76See all movers →
Business Strength
80Why 80?
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 31.9% over 4 years: customers keep spending more with this company.
Profit climbed about 94.3% over 4 years: the business keeps more money as it grows.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 12.3% over the last 8 quarters: customers keep spending more with this company.
Profit grew about 91.7% over the last 8 quarters: the business is keeping more of what it earns.
Financial Safety
83Why 83?
Show 2 charts
Debt vs Equity, with D/E ratio
Borrowings fell about 14.1% over 4 years: the company is steadily getting safer.
Short-term assets vs bills, with Current Ratio
Cash & DividendsLowest pillar
75Why 75?
Show 3 charts
Operating vs Free Cash Flow
The business generates real cash, and more of it each year: a very healthy sign.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price Fairness
83Why 83?
Show chart
Score vs Share Price
The share price is down about 9.8% over the past year.
What happened, and how the price moved
After the last 3 results shown, the price beat the KLCI in the week of the news 1 times.
- 3 Sep 2026Ex-dividend 1.5 sen a share1.2% yield at that priceWeek▼1.2%KLCI −1.0%Month▼5.9%KLCI −3.1%
- 18 Aug 2026Duopharma Biotech’s 2Q profit jumps 48% as margin expands · The Edge Malaysia +5 moreWeek▼0.7%KLCI +0.5%Month▼1.2%KLCI −2.4%
- 14 May 2026Duopharma Biotech registers stronger 1Q bottomline on lower sales cost · The Star +1 moreScore 63 → 76Week▼0.8%KLCI −0.4%Month▼6.1%KLCI −3.1%
- 12 Mar 2026Ex-dividend 3.0 sen a share2.1% yield at that priceWeek▼8.8%KLCI −1.1%Month▼12.9%KLCI −1.3%
- 13 Nov 2025Duopharma Biotech posts 45% jump in 3Q net profit on wider margins, favourable product mix · The Edge MalaysiaWeek▲0.8%KLCI +0.4%Month▼1.5%KLCI −0.2%
Risk
100Why 100?
Show chart
Revenue vs Inventory, with Inventory % of Revenue
Get an email when DPHARMA's score changes, and why
Own more than one stock? Check them all at once ›Sector peers
DPHARMA (7148.KL) scores 85/100 (Strong) on Score Your Stock's educational fundamentals model: in the top 3% of 1120 scored Bursa Malaysia stocks.
Its strongest pillar is Risk (100/100); its weakest is Cash & Dividends (75/100).
DPHARMA ranks #1 of 30 scored Health Care stocks on Score Your Stock.
Yes. DPHARMA (7148.KL) has a dividend yield of 3.9%, from dividends with an ex-date in the last 12 months. It pays out 43% of its profit as dividends. Its Cash & Dividends pillar scores 75/100.
Open a trading account and a CDS account with any Bursa Malaysia broker, then place a buy order for 7148.KL in lots of 100 shares. Broker fees for the same trade differ a lot between brokers: compare them for your trade size at https://scoreyourstock.com/tools/brokerage-fee-calculator.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk (for banks, Financial Safety checks impaired loans, loan loss coverage and the CET1 capital ratio instead of debt and liquidity). Full methodology, the default weights, and how to set your own: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Makes generic and ethical medicines, insulin, and consumer health brands such as Flavettes vitamins. On Score Your Stock's fundamentals check, it scores 85/100, rated Strong. Its biggest strength is Risk (100/100); its main watch-out is Cash & Dividends (75/100). Shares currently cost about 10 years of its current profit to buy (P/E 10.3×). It also pays back about 3.9% of the share price as dividends each year. Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/klse/7148-dpharma
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Inventory | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Current Ratio | Interest Coverage | Dividend Payout Ratio | Div yield | P/E Ratio | P/B Ratio | PEG Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | RM 929.4m | RM 102.2m | RM 82.9m | RM 58.7m | RM -24.2m | RM 256.0m | RM 471.6m | RM 135.0m | RM 786.1m | RM 844.1m | RM 301.3m | RM 1.5b | RM 671.6m | RM 305.3m | - | 13% | 11% | 0.6× | 2.8× | 6.8× | 43% | - | - | - | - |
| 2025 | RM 931.7m | RM 87.5m | RM 106.8m | RM 73.8m | RM -33.0m | RM 290.9m | RM 492.9m | RM 147.4m | RM 757.6m | RM 819.4m | RM 314.0m | RM 1.4b | RM 690.7m | RM 293.2m | RM 3.5m | 12% | 9% | 0.7× | 2.6× | 5.6× | 38% | 3% | 13.2× | 1.5× | 1.7 |
| 2024 | RM 813.7m | RM 62.6m | RM 83.3m | RM 49.5m | RM -33.9m | RM 264.5m | RM 515.8m | RM 48.0m | RM 709.2m | RM 726.4m | RM 178.0m | RM 1.4b | RM 668.7m | RM 248.5m | RM 2.8m | 9% | 8% | 0.7× | 4.1× | 4.0× | 43% | 2% | 18.1× | 1.6× | - |
| 2023 | RM 704.7m | RM 52.6m | RM 48.8m | RM 9.2m | RM -39.6m | RM 270.5m | RM 548.8m | RM 65.5m | RM 687.1m | RM 677.1m | RM 166.7m | RM 1.3b | RM 658.0m | RM 243.1m | RM 2.3m | 8% | 7% | 0.8× | 4.1× | 4.6× | 17% | 2% | 21.2× | 1.6× | - |